An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will report Q4 and full-year 2023 financial results on February 22, 2024. A live conference call and webcast will follow. The Company is focused on improving the lives of people with serious medical conditions.
Positive
None.
Negative
None.
STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.
Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 2023 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc. Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contact: Christopher James, M.D. Vice President, Investor Relations ir@collegiumpharma.com
When will Collegium Pharmaceutical report Q4 and full-year 2023 financial results?
Collegium Pharmaceutical will report Q4 and full-year 2023 financial results after the market closes on Thursday, February 22, 2024.
What is the ticker symbol for Collegium Pharmaceutical?
The ticker symbol for Collegium Pharmaceutical is COLL.
How can I access the conference call and webcast for Collegium Pharmaceutical's financial results?
To access the conference call, dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference 'Collegium Pharmaceutical Q4 2023 Earnings Call.' An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com.
Where can I find the replay of the webcast for Collegium Pharmaceutical's financial results?
The webcast will be available for replay on the Company’s website approximately two hours after the event.
collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex
